Hemodialysis Vascular Access Dysfunction: From Pathophysiology to Novel TherapiesRoy-Chaudhury P. · Kelly B.S. · Zhang J. · Narayana A. · Desai P. · Melhem M. · Duncan H. · Heffelfinger S.C.
University of Cincinnati Medical Center, Cincinnati, Ohio, USA
Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis population at a cost of over USD 1 billion per annum. Most hemodialysis grafts fail due to a venous stenosis (venous neointimal hyperplasia) which then results in thrombosis of the graft. Despite the magnitude of the clinical problem there are currently no effective therapies for this condition. The current review (a) describes the pathogenesis and pathology of venous stenosis in dialysis access grafts and (b) discusses the development and application of novel therapeutic interventions for this difficult clinical problem. Special emphasis is laid on the fact that PTFE dialysis access grafts could be the ideal clinical model for testing out novel local therapies to block neointimal hyperplasia.
Copyright © 2003 S. Karger AG, Basel
Prabir Roy-Chaudhury, MD, PhD
Division of Nephrology, MSB G-258, University of Cincinnati
231 Albert Sabin Way
Cincinnati, OH 45267-0585 (USA)
Tel. +1 513 5584006, Fax +1 513 5584309, E-Mail firstname.lastname@example.org
Number of Figures : 3, Number of Tables : 0, Number of References : 113
Founded 1983; edited by K. Schaefer (1983–1988)
Official Journal of the International Society of Blood Purification and the Vascular Access Society (VAS)
Vol. 21, No. 1, Year 2003 (Cover Date: 2003)
Journal Editor: K.M.L. Leunissen, Maastricht
ISSN: 0253–5068 (print), 1421–9735 (Online)
For additional information: http://www.karger.com/bpu